💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Memantine

CHEMBL807 Phase 4 已批准 Small molecule
Half-Life
60-80 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
179.3 g/mol
LogP
3.3
Phase
4

An NMDA receptor antagonist used to treat moderate-to-severe Alzheimer's disease by blocking excessive glutamate activity that can damage brain cells, helping to improve memory, thinking, and daily functioning. It is often used in combination with cholinesterase inhibitors.

分子量

179.3080 g/mol

LogP

3.30

TPSA

26.00 Ų

Lipinski 五规则

符合

治疗领域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Pain Management Non-Small Cell Lung Cancer Osteoporosis Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Melanoma Oncology Systemic Lupus Erythematosus Multiple Sclerosis Stroke Major Depressive Disorder Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer

药物分类

N — N - Nervous System

作用机制

Non-competitive NMDA receptor antagonist.

Pharmacokinetics (PK)

Half-Life 60-80 hours

Pharmacodynamics (PD)

机制

Non-competitive NMDA receptor antagonist.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC12CC3CC(C)(C1)CC(N)(C3)C2

                

                

                
                

                    
InChI

                    
InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C12H21N

                    

                    
                    

                        
HBD / HBA

                        
1 / 1

                    

                    
                    

                        
可旋转键数

                        
0

                    

                    
                    
                    

                        
重原子数

                        
13

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            GABRA1 (GABA-A Receptor)
                            Antagonist
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            HRH1 (Histamine H1 Receptor)
                            Antagonist
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Memantine + Metformin
                            
                        

                        
                        
Memantine may compete with metformin for renal tubular cationic secretion, potentially increasing metformin plasma concentrations modestly.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Memantine + Hydrochlorothiazide
                            
                        

                        
                        
Hydrochlorothiazide may reduce renal clearance of memantine through alkalinisation of urine, as memantine elimination is pH-dependent; the clinical impact is generally minor.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
An NMDA receptor antagonist used to treat moderate-to-severe Alzheimer's disease by blocking excessive glutamate activity that can damage brain cells, helping to improve memory, thinking, and daily functioning. It is often used in combination with cholinesterase inhibitors.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Non-competitive NMDA receptor antagonist.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Memantine: Half-life: 60-80 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Memantine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL807.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4054.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.